New Diet Pill: Active Ingredient Against Overweight
- Data from teh "Achieve-1" phase 3 clinical trial of Orforglipron, an investigational oral medication, will be presented at the American Diabetes Association's (ADA) 85th Scientific Sessions in June,...
- Orforglipron is a once-daily, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist.
- The "Achieve-1" study involved 559 patients with type 2 diabetes who were treated for 40 weeks with either 3 mg, 12 mg, or 36 mg of Orforglipron, or...
orforglipron Shows Promise in Type 2 Diabetes Treatment
Table of Contents
- orforglipron Shows Promise in Type 2 Diabetes Treatment
- Orforglipron and Type 2 diabetes: Your Questions Answered
- What is Orforglipron?
- How does orforglipron work?
- What are the potential benefits of Orforglipron compared to existing oral diabetes medications?
- What were the results of the “Achieve-1” clinical trial?
- Who participated in the “Achieve-1″ study?
- What dosages of Orforglipron were tested in the “Achieve-1” study?
- Are there any side effects associated with Orforglipron?
- How do the side effects of Orforglipron compare to those of other GLP-1 receptor agonists like Semaglutide?
- What do experts think of Orforglipron’s potential?
- What are the next steps for Orforglipron?
- When is Orforglipron expected to be approved?
- When will more data be available?
- Is there any information available on the potential pricing of orforglipron?
- How does Orforglipron compare to other diabetes medications, like Rybelsus (semaglutide)?
Data from teh “Achieve-1” phase 3 clinical trial of Orforglipron, an investigational oral medication, will be presented at the American Diabetes Association’s (ADA) 85th Scientific Sessions in June, followed by publication in a peer-reviewed journal.
Orforglipron is a once-daily, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. It aims to offer a more convenient alternative to existing oral GLP-1 agonists like semaglutide (Rybelsus), wich requires specific management guidelines, including taking it on an empty stomach 30 minutes before the first meal. Orforglipron can be taken without regard to food or water intake.
Meaningful Improvements in Blood Sugar and Weight Observed
The “Achieve-1” study involved 559 patients with type 2 diabetes who were treated for 40 weeks with either 3 mg, 12 mg, or 36 mg of Orforglipron, or a placebo. The patients’ average baseline HbA1c was 8.0 percent. Results showed HbA1c reductions ranging from 1.3 percentage points (3 mg) to 1.6 percentage points (12 mg) compared to a 0.1 percentage point reduction in the placebo group. All reductions were statistically significant. Notably, more than 65 percent of patients on the highest dose achieved an HbA1c level of 6.5 percent or lower.
The study also demonstrated significant weight loss.Patients taking Orforglipron experienced weight reductions of 4.7 to 7.9 percent, compared to 1.6 percent in the placebo group. In terms of absolute weight loss, this translated to a decrease of 4.4 to 7.3 kg versus 1.3 kg with placebo. The developing pharmaceutical company suggests further weight loss might potentially be possible, stating, ”It truly seems that the full weight loss has not yet been reached.”
Side Effects Generally Manageable
The most common side effects were consistent with the known profile of GLP-1 receptor agonists, primarily gastrointestinal issues. These included diarrhea (up to 26 percent),nausea (up to 18 percent),and vomiting (up to 14 percent),compared to substantially lower rates in the placebo group. The discontinuation rate due to adverse events was up to 8 percent. Researchers noted the side effect profile was gastrointestinal, similar to Semaglutide, but with diarrhea being more prevalent. Vomiting was reported less frequently than with Semaglutide. No indications of liver toxicity were observed.
Expert optimism tempered by Need for Further Data
Professor Naved Sattar, a cardiometabolic expert at the University of Glasgow, expressed optimism, telling the UK science Media Center, “These are important results. New oral active ingredients that reduce both blood sugar and weight significantly more than most existing diabetes medication are crucial for the future care for type 2 diabetes.”
Sattar also emphasized the need for further research, stating, “There is a reservation that we do not yet know how this new therapy affects cardiovascular events - this will show future studies. It is indeed also gratifying to hear of a cheap security profile,especially with regard to the liver. It becomes exciting to see the full data.”
potential Approval timeline
The “Achieve-1” phase 3 trial is part of a larger progress program encompassing seven studies. Additional data, especially regarding weight loss from the “Attain” program, are anticipated in 2025. The pharmaceutical company plans to submit applications for approval for weight management to global regulatory bodies in 2025,with the application for type 2 diabetes approval expected in 2026.
The company expressed confidence in its ability to manage a global launch without supply constraints. Pricing information is not yet available.
Orforglipron and Type 2 diabetes: Your Questions Answered
What is Orforglipron?
Orforglipron is an investigational, once-daily, oral medication being studied for the treatment of type 2 diabetes. It’s a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. This means it works in a similar way to other GLP-1 receptor agonists, but with the advantage of being taken orally, once a day.
How does orforglipron work?
While the provided text doesn’t delve into the exact mechanism, it identifies Orforglipron as a GLP-1 receptor agonist. Thes types of medications work by mimicking the effects of the GLP-1 hormone in the body. This can lead to:
Improved blood sugar control: GLP-1 agonists help the pancreas release insulin when blood sugar levels are high.
Weight loss: Some GLP-1 agonists can also slow down stomach emptying and affect appetite, wich can lead to weight loss.
What are the potential benefits of Orforglipron compared to existing oral diabetes medications?
The primary advantage highlighted in the source material is convenience. Orforglipron is designed to be a more convenient alternative to existing oral GLP-1 agonists like semaglutide (Rybelsus). Semaglutide has specific guidelines (e.g., taking it on an empty stomach 30 minutes before a meal), while Orforglipron can be taken without regard to food or water intake. Furthermore, the provided content suggests Orforglipron has demonstrated significant reductions in both HbA1c (blood sugar) and weight.
What were the results of the “Achieve-1” clinical trial?
The “Achieve-1” phase 3 clinical trial evaluated the effectiveness of Orforglipron in patients with type 2 diabetes.Key findings include:
HbA1c Reduction: Patients taking Orforglipron experienced significant reductions in HbA1c levels. Reductions ranged from 1.3 to 1.6 percentage points, depending on the dosage, compared to a 0.1 percentage point reduction in the placebo group.
Weight Loss: Participants also experienced significant weight loss. Weight reductions ranged from 4.7 to 7.9 percent, compared to 1.6 percent in the placebo group.Translated to absolute weight loss, this was a decrease of 4.4 to 7.3 kg versus 1.3 kg with the placebo.
HbA1c Goal Achievement: more than 65% of patients on the highest dose of Orforglipron achieved an HbA1c level of 6.5% or lower.
Who participated in the “Achieve-1″ study?
The “Achieve-1” study involved 559 patients with type 2 diabetes.
What dosages of Orforglipron were tested in the “Achieve-1” study?
Patients in the “Achieve-1” study were treated with one of the following:
3 mg of Orforglipron
12 mg of Orforglipron
36 mg of Orforglipron
Placebo
Are there any side effects associated with Orforglipron?
Yes, like other GLP-1 receptor agonists, Orforglipron has side effects, with the most common being gastrointestinal issues. These include:
Diarrhea (up to 26%)
Nausea (up to 18%)
Vomiting (up to 14%)
The discontinuation rate due to adverse events was up to 8%.
How do the side effects of Orforglipron compare to those of other GLP-1 receptor agonists like Semaglutide?
The side effect profile is gastrointestinal, similar to Semaglutide, but with diarrhea being more prevalent with Orforglipron.Vomiting was reportedly less frequent than with semaglutide.
What do experts think of Orforglipron’s potential?
Professor Naved Sattar, a cardiometabolic expert, expressed optimism, stating that the results are crucial and that new oral active ingredients that reduce both blood sugar and weight are crucial for the future care of type 2 diabetes.
What are the next steps for Orforglipron?
The pharmaceutical company is conducting a larger program encompassing seven studies, including the “Attain” program, which focuses on weight loss.
When is Orforglipron expected to be approved?
The application for approval for weight management is planned for submission to global regulatory bodies in 2025, with the application for type 2 diabetes approval expected in 2026.
When will more data be available?
Additional data, especially regarding weight loss from the “Attain” program, are anticipated in 2025.
Is there any information available on the potential pricing of orforglipron?
No, information on pricing is not yet available.
How does Orforglipron compare to other diabetes medications, like Rybelsus (semaglutide)?
while the provided text doesn’t directly offer a detailed comparison table, it does provide enough information to create a summary:
| Feature | Orforglipron | Semaglutide (Rybelsus) |
| ——————- | ——————————- | ———————————- |
| Type | Oral GLP-1 Receptor Agonist | Oral GLP-1 Receptor Agonist |
| Administration | Once-daily, without regard to food | Once-daily, on an empty stomach |
| Primary Benefit | blood sugar and weight reduction | Reduces blood sugar and aids weight loss |
| Side Effects | Primarily gastrointestinal | Similar, but diarrhea more prevalent |
| Status | Investigational | Approved |
| availability | not yet approved | Available |